Skip to main content
SpringerLink
Log in

Welche Faktoren sind zu berücksichtigen?

Therapie des multiplen Myeloms bei älteren Patienten

  • zertifizierte fortbildung
  • Published:
InFo Onkologie Aims and scope

Zusammenfassung

Das multiple Myelom ist eine Erkrankung, die typischerweise ältere Patienten betrifft. Obwohl sich durch die Hochdosistherapie mit autologer Stammzelltransplantation die Prognoese deutlich verbessert hat, ist diese Form der Therapie nicht für alle älteren Patienten sinnvoll. Bei ihnen müssen eine Vielzahl von Faktoren für die Therapieentscheidung berücksichtigt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Wörmann et al. Onkopedia Leitlinie Multiples Myelom. (Stand Mai 2018); https://www.onkopedia.com/de/onkopedia/guidelines/multiples-myelom/@@view/html/index.html abgerufen am 12.09.2018

  2. Gesellschaft der epidemiologischen Krebsregister e. V. (GEKID) und Zentrum für Krebsregisterdaten (ZfKD) im Robert Koch-Institut. Krebs in Deutschland für 2013/2014; https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_node.html abgerufen am 12.09.2018

  3. Larocca et al. Patient-centered practice in elderly myeloma patients: An overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018; http://doi.org/10.1038/s41375-018-0142-9.

    Article  Google Scholar 

  4. Engelhardt M et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99(2):23–42.

    Article  Google Scholar 

  5. Palumbo A et al. International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. J Clin Oncol. 2014;32(6):587–600.

    Article  Google Scholar 

  6. Pawlyn C et al. Nuances in the Management of Older Patients With Multiple Myeloma. Curr Hematol Malig Rep. 2016;11(3):241–51.

    Article  Google Scholar 

  7. Palumbo A et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–74.

    Article  CAS  Google Scholar 

  8. Engelhardt M et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101(9):1110–9.

    Article  Google Scholar 

  9. Auner HW et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50(2):209–15.

    Article  CAS  Google Scholar 

  10. Merz M et al. Survival of elderly patients with multiple myeloma—Effect of upfront autologous stem cell transplantation. Eur J Cancer. 2016;62:1–8.

    Article  Google Scholar 

  11. Merz M et al. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol. 2014;25(1):189–95.

    Article  CAS  Google Scholar 

  12. Auner HW et al. Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018;103(3):514–21.

    Article  Google Scholar 

  13. Gay F et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood. 2013;122(8):1376–83.

    Article  CAS  Google Scholar 

  14. Gay F et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103(2):197–211.

    Article  Google Scholar 

  15. Straka C et al. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica. 2016;101(11):1398–406.

    Article  CAS  Google Scholar 

  16. McCarthy PL et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017;35(29):3279–89.

    Article  Google Scholar 

  17. Palumbo A et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013;98(1):87–94.

    Article  CAS  Google Scholar 

  18. Fayers PM et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239–47.

    Article  CAS  Google Scholar 

  19. Benboubker L et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–17.

    Article  CAS  Google Scholar 

  20. Facon T et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301–10.

    Article  CAS  Google Scholar 

  21. San Miguel JF et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.

    Article  CAS  Google Scholar 

  22. San Miguel JF et al. Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. J Clin Oncol. 2013;31(4):448–55.

    Article  CAS  Google Scholar 

  23. Bringhen S et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745–53.

    Article  CAS  Google Scholar 

  24. Moreau P et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–40.

    Article  Google Scholar 

  25. Niesvizky R et al. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. J Clin Oncol. 2015;33(33):3921–9.

    Article  CAS  Google Scholar 

  26. Magarotto V et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102–8.

    Article  CAS  Google Scholar 

  27. Bringhen S et al. Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study. Blood. 2017;130(Suppl 1):901.

    Google Scholar 

  28. Stewart AK et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaN Engl J Med. 2015;372(2):142–52.

    Article  Google Scholar 

  29. Dimopoulos MA et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017;177(3):404–13.

    Article  CAS  Google Scholar 

  30. Dimopoulos MA et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.

    Article  CAS  Google Scholar 

  31. Moreau P et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;374(17):1621–34.

    Article  CAS  Google Scholar 

  32. San-Miguel JF et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–206.

    Article  CAS  Google Scholar 

  33. Richardson PG et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127(6):713–21.

    Article  CAS  Google Scholar 

  34. San-Miguel JF et al. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016;3(11):e506–e515.

    Article  Google Scholar 

  35. Lokhorst HM et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015;373(13):1207–19.

    Article  CAS  Google Scholar 

  36. Lonial S et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–60.

    Article  CAS  Google Scholar 

  37. Palumbo A et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(8):754–66.

    Article  CAS  Google Scholar 

  38. Dimopoulos MA et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(14):1319–31.

    Article  CAS  Google Scholar 

  39. Lonial S et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621–31.

    Article  CAS  Google Scholar 

  40. Miguel JS et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–66.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Hämatologie, Onkologie und Stammzelltransplantation am Klinikum Schwabing, München, Deutschland

    Charlotte Weyermann, Sven Thorspecken &  Christian Straka

Authors
  1. Charlotte Weyermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sven Thorspecken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Straka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Straka.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließ. Die Autoren legen folgende potenzielle Interessenkonflikte offen: C. Weyermann: Vortragstätigkeit für Bristol-Myers Squibb und Amgen; Advisory Board: Bristol-Myers Squibb und Amgen; Reisekostenerstattung für einen Kongress durch Bristol-Myers Squibb; S. Thorspecken: keine; C. Straka: keine; Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weyermann, C., Thorspecken, S. & Straka, C. Therapie des multiplen Myeloms bei älteren Patienten. Info Onkol. 21, 35–43 (2018). https://doi.org/10.1007/s15004-018-5941-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-018-5941-7

Search

Navigation